Wegovy

Latest three-month snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By model

How often each model brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the models' own words, grouped by theme.

• fda-approved for weight management ×29

  “FDA-Approved for Weight Loss”

• weekly dosing ×27

  “Weekly Injections”

• fda-approved ×20

  “* **Ozempic** is specifically FDA-approved to lower blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events (like stroke or heart attack) in diabetics with established heart disease.”

• semaglutide ×16

  “* **How it compares:** Head-to-head data and clinical comparisons show that Zepbound generally leads to greater weight loss than Wegovy (semaglutide), where average weight loss typically hovers around 15%.”

• cardiovascular protection ×13

  “* **Cardiovascular Protection:** Wegovy is FDA-approved to **reduce the risk of major cardiovascular events**—including heart attacks, strokes, and cardiovascular death—in adults with established heart disease and obesity.”

• greater weight loss ×13

  “Because of this higher dose, clinical trials show patients on Wegovy achieve greater average weight loss (about 15% to 18% of their body weight) compared to those on Ozempic (about 8% to 14%).”

• once-weekly injection ×12

  “It is available as a **once-weekly injection** or as a **once-daily oral pill** (which is formulated at a high 25 mg dose specifically for weight loss).”

• 15% to 21% average weight loss ×10

  “If you must pick exactly one, you should choose **Wegovy**.”

• significant weight loss ×10

  “* **Substantial Weight Loss:**”

• weight loss ×10

  “If your primary goal is weight loss, Wegovy is the superior clinical choice.”

In their words

262 exact quoted mentions in this snapshot, grouped by coded tone. Recent quotes are deduplicated and mixed across models.

What they recommend

“**Wegovy (semaglutide):** new self-pay patients can get the **0.25 mg or 0.5 mg pens for $199/month for the first two fills** through NovoCare; afterward, listed pricing is generally **$349/month** for standard doses. If you have eligible c”

“Trials showed Wegovy patients regained only 5% of their lost weight when they switched to Foundayo.”

“ask about the obesity-labeled versions (Zepbound/Wegovy), rather than buying Mounjaro or Ozempic off-label”

“Wegovy has a major clinical advantage regarding heart health. It is FDA-approved not just for weight loss, but specifically to **reduce the risk of major adverse cardiovascular events (MACE)**—such as cardiovascular death, heart attacks, an”

“**Wegovy.** Here's why, if I have to pick just one”

Where they hedge

“Wegovy (semaglutide) is one of the pricier weight-loss GLP-1 drugs”

“New daily pills including Wegovy (semaglutide) and Foundayo (orforglipron) offer an alternative to injectable GLP-1 medications.”

“So the alternatives that are *reliably cheaper* are mostly older, non-GLP-1 medications—not Wegovy or Zepbound.”

“Yes. The **least expensive alternatives to Wegovy (semaglutide)** are usually older oral medicines or a generic daily GLP-1—not another weekly GLP-1.”

“You do not have to worry about self-injecting once a week like you would with Wegovy or Zepbound.”

What they warn about

“Brand-name weekly GLP-1s (like Ozempic, Wegovy, or Mounjaro) do not have generic options yet and routinely cost upwards of $900 to $1,000+ per month without insurance.”

“**Do not combine Zepbound with another GLP-1** (such as Wegovy, Ozempic, or Foundayo) unless a clinician explicitly directs a transition plan.”

“Head-to-head data and real-world studies show that tirzepatide is significantly more effective for weight loss than semaglutide (the active ingredient in Ozempic and Wegovy), which typically results in about 15% weight loss.”

“The FDA approved a 7.2 mg dose of Wegovy in March 2026, a dose that wasn't included in the trial Lilly's ads cite.”

“**Wegovy** and **Zepbound** may be more effective for many people and are weekly rather than daily injections, but without coverage they are often still expensive.”

The substitution map

Which competitors models suggest when shoppers ask for something cheaper.

Where this comes from

52 of 262 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites models name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.